Navigation Links
MannKind Addresses Pfizer's Announcement Regarding Exubera
Date:4/10/2008

m.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding a partnership for the commercialization of Technosphere(R) Insulin. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations and involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of clinical trials, whether results of further clinical trials of Technosphere(R) Insulin will reveal safety concerns, whether the clinical data regarding Technosphere(R) Insulin will support regulatory approval, difficulties or delays in seeking or obtaining regulatory approval, whether MannKind will be able to enter into and maintain a collaboration with a pharmaceutical partner for commercialization of Technosphere(R) Insulin and its other peptide hormone drug candidates on attractive terms for MannKind if at all, and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2007 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
2. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
3. Roche responds to announcement of IDEAL hepatitis C trial results
4. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
5. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
6. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
7. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
8. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... TechniScan, Inc. (OTC Bulletin ... device company engaged in the development and commercialization ... today that Joe Pepper, PhD, has been appointed ... Board Chairman Ken Hungerford commented, "Joe has extensive ... including GE OEC Medical and U-Systems, both of ...
(Date:12/16/2009)... -- Naurex Inc., a new clinical stage company ... disorders based on its novel GFPA NMDA receptor ... Phase I clinical trial of its lead compound ... in the study. GLYX-13, a glycine site ... NMDA receptor, is initially being developed as a ...
(Date:12/16/2009)... PALO ALTO, Calif., Dec. 16 The ... Intradigm Corporation are delighted to announce the merger ... in the field of RNAi (RNA interference). ... will have multiple RNAi discovery, development and delivery ... and a broad portfolio of intellectual property. ...
Breaking Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 2Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 4Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 5Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 6Ortho Clinical Diagnostics Receives FDA Approval for First Anti HIV 1+2 Test for Use on Random Access Integrated Laboratory Testing System 5472 1Ortho Clinical Diagnostics Receives FDA Approval for First Anti HIV 1+2 Test for Use on Random Access Integrated Laboratory Testing System 5472 2Ortho Clinical Diagnostics Receives FDA Approval for First Anti HIV 1+2 Test for Use on Random Access Integrated Laboratory Testing System 5472 3Ortho Clinical Diagnostics Receives FDA Approval for First Anti HIV 1+2 Test for Use on Random Access Integrated Laboratory Testing System 5472 4Experts summarize state of the science in autism disorders 59459 1Experts summarize state of the science in autism disorders 59459 2Miriam Hospital researcher receives more than 2412 million to study weight control 10359 1Miriam Hospital researcher receives more than 2412 million to study weight control 10359 2Miriam Hospital researcher receives more than 2412 million to study weight control 10359 3
... Plan for Biomarker Study -, MONTVALE, N.J., ... ) today announced that it plans to,conduct a ... nicotinic alpha-7,partial agonist, on two biomarkers of schizophrenia, ... schizophrenia. The biomarker study,and additional formulation and manufacturing ...
... Detecting the ... Mosquito-Borne Infectious Disease, CYPRESS, Calif., Feb. 15 Focus ... DGX ),today announced the first laboratory developed test in ... molecular polymerase chain reaction (PCR) test will enable physicians,in the ...
Other Medicine Technology:Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 2Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 3Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 4Focus Diagnostics Launches Laboratory Test for Chikungunya Virus 2Focus Diagnostics Launches Laboratory Test for Chikungunya Virus 3Focus Diagnostics Launches Laboratory Test for Chikungunya Virus 4
(Date:12/16/2009)... S.C., Dec. 16 Medical travel facilitator ... hospitals in Puerto Rico into its network of ... substantially lower than those at mainland U.S. facilities. ... offer medical travel assistance and preferred pricing for ... seek treatment at either HIMA San Pablo Bayamon ...
(Date:12/16/2009)... -- New research published online, December 10, ... and molecules present in pistachios, have anti-inflammatory ... of an inflammatory marker known as "Ifit-2" ... is a complex biological response to harmful ... it underlies functional changes associated with many ...
(Date:12/16/2009)... 16 In a random sampling of ... ME, and Philadelphia, PA, numerous pallets tested positive ... that could potentially create health hazards for consumers. ... previous wood pallet testing conducted in the Washington-Baltimore ... risks to our nation,s food supply from wood ...
(Date:12/16/2009)... shrouded man found in a tomb on the edge of ... case of leprosy. Details of the research will be published ... The molecular investigation was undertaken by Prof. Mark Spigelman and ... for the Study of Infectious and Tropical Diseases at the ... Vernon of Lakehead University, Canada, Prof. Azriel Gorski of New ...
(Date:12/16/2009)... Boston University School of Medicine,s (BUSM) Pulmonary Center ... the National Heart, Lung, and Blood Institute to ... with lung disease. , Darrell Kotton, MD, ... Mostoslavsky, MD, PhD, assistant professor of medicine, are ... Together Kotton and Mostoslavsky lead a multicenter investigative ...
Breaking Medicine News(10 mins):Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 3Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 2Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 3Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 4Health News:DNA of Jesus-era shrouded man in Jerusalem reveals earliest case of leprosy 2Health News:DNA of Jesus-era shrouded man in Jerusalem reveals earliest case of leprosy 3Health News:Boston University School of Medicine's pulmonary center receives $1.4 million grant 2
... warning on product label , , FRIDAY, Feb. 1 ... smoking-cessation drug Chantix is linked to serious "neuropsychiatric" ... suicide, U.S. health officials said Friday. , The ... manufacturer, Pfizer Inc., to make the warning about ...
... That the cell nurturing growth factor interleukin-7 can help ... remember the pathogenic villains it encounters is well known., ... on the cells of the immune system is not ... implications for developing vaccines against HIV and cancer, a ...
... suggests images more intense, but oddly lacking planes flying into ... attacks of Sept. 11, 2001, not only caused huge political ... , That,s the suggestion from a small study published in ... Ernest Hartmann of Tufts University and Newton-Wellesley Hospital in Boston ...
... 4 models and found no problems , , FRIDAY, Feb. ... the iPod don,t cause electronic interference in implanted cardiac ... in the current issue of BioMedical Engineering OnLine ... four different iPod models -- a fourth-generation iPod; iPod ...
... patients with chronic hepatitis C who participated in a ... long-term treatment trial for patients who had failed to ... interviewers at the time of enrollment that they were ... herbal products for health purposes. This information was somewhat ...
... Columbia University Medical Center research team has uncovered how stimulation ... deficits in working memory, associated with an extended sleep deprivation. ... memory that relates to the ability to store task-specific information ... in a huge mall lot or remembering a phone number ...
Other Medicine News:Health News:Quit-Smoking Drug May Raise Suicide Risk 2Health News:Quit-Smoking Drug May Raise Suicide Risk 3Health News:T cell immunity enhanced by timing of interleukin-7 therapy 2Health News:T cell immunity enhanced by timing of interleukin-7 therapy 3Health News:Silymarin does not affect virus activity or ALT levels in 2Health News:Silymarin does not affect virus activity or ALT levels in 3Health News:Brain region that can be stimulated to reduce the cognitive deficits of sleep deprivation identified 2Health News:Brain region that can be stimulated to reduce the cognitive deficits of sleep deprivation identified 3
... PachPen uses state-of-the-art waveform analysis ... at a 65MHz rate to ... stores and averages nine measurements ... pen fits comfortably into the ...
... A companion product to the new IM3300 EDTV ... Watt Xenon Light Source offers some truly innovative ... is simply to understand and easy to operate. ... has incorporated a new Stand-By Feature, which allows ...
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
1000 L, Bulk Recommended for 500 and 1000 L pipettes...
Medicine Products: